Skip to main content

Table 1 Patient characteristics

From: Parathyroid imaging with 18F-fluorocholine PET/CT as a first-line imaging modality in primary hyperparathyroidism: a retrospective cohort study

  All patients
n = 271
Operated patients
n = 139
Patients treated with calcimimetics
n = 48
Patients without active treatment
n = 84
Age (years) 62 ± 12 (29–86)* 60 ± 11 (29–81)* 67 ± 11 (43–86)* 64 ± 11 (31–83)*
Sex (n)
 Female 205 (76%) 107 (77%) 34 (71%) 64 (76%)
 Male 66 (24%) 32 (23%) 14 (29%) 20 (24%)
PTH (pmol/L) (normal range 1.3–6.8 pmol/L) 16.1 ± 11.3 (2.4–121.9)* n = 271 17.9 ± 13.5 (4.5–121.9)* n = 139 16.7 ± 11.2 (4.3–57.1)* n = 48 12.6 ± 5.1 (2.4–26.0)* n = 84
Serum calcium (mmol/L) (normal range 2.10–2.50 mmol/L) 2.66 ± 0.21 (2.11–3.86)* n = 271 2.72 ± 0.21 (2.11–3.86)* n = 139 2.67 ± 0.20 (2.14–3.14)* n = 48 2.56 ± 0.18 (2.16–2.96)* n = 84
Serum phosphate (mmol/L) (normal range 0.7–1.4 mmol/L) 0.9 ± 0.2 (0.3–1.5)* n = 223 0.8 ± 0.2 (0.3–1.2)* n = 120 0.9 ± 0.2 (0.6–1.2)* n = 38 0.9 ± 0.2 (0.5–1.5)* n = 65
24-h urinary calcium (mmol/24 h) (normal range 2.5–7.5 mmol/24 h) 7.2 ± 4.0 (0.1–18.5)* n = 198 8.8 ± 3.9 (0.1–18.5)* n = 99 6.4 ± 3.5 (0.7–14.3)* n = 37 5.6 ± 3.8 (0.5–17.5)* n = 62
SUVmax (early images) 6.1 ± 2.9 (1.5–20.5)* n = 197 6.3 ± 2.7 (1.5–12.7)* n = 127 5.9 ± 2.6 (2.7–12.5)* n = 36 5.7 ± 3.8 (2.1–20.5)* n = 34
SUVmax (late images) 4.9 ± 2.2 (1.3–13.7)* n = 203 5.0 ± 2.2 (1.3–12.0)* n = 132 4.7 ± 2.4 (1.6–13.7)* n = 37 4.4 ± 2.0 (1.8–9.9)* n = 34
  1. PTH parathyroid hormone, SUVmax maximum standardized uptake value
  2. *mean ± SD (range)